Form 4: Adverum Biotechnologies Director James Paul Scopa Acquires Stock Options

Director James Paul Scopa acquired 10,520 stock options in Adverum Biotechnologies, Inc. on June 17, 2024, according to a Form 4 filing with the SEC.

Summary

• James Paul Scopa, a director of Adverum Biotechnologies, Inc., acquired 10,520 stock options on June 17, 2024.
• The exercise price of these options is $7.32.
• The options vest on the earlier of June 17, 2025, or the 2025 annual meeting of stockholders, subject to accelerated vesting upon a change of control and continued service with the Issuer.
• A Power of Attorney was granted on March 15, 2024, authorizing certain officers of Adverum Biotechnologies to execute and file Forms 3, 4, and 5 on behalf of James Scopa.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider activity.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The vesting schedule and exercise price of the options are typical for executive compensation packages.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future prospects.

Key Dates